Immuron Limited (IMC.AX)
AUD 0.08
(-3.7%)
AUD 0.08
(-3.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 173.49 Thousand AUD | -8.25% |
| 2023 | 189.09 Thousand AUD | -9.86% |
| 2022 | 209.78 Thousand AUD | 923.45% |
| 2021 | 20.49 Thousand AUD | -66.45% |
| 2020 | 61.1 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| 2018 | - AUD | -100.0% |
| 2017 | 365.86 Thousand AUD | -80.75% |
| 2016 | 1.9 Million AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | -100.0% |
| 2013 | 1.14 Million AUD | 104.83% |
| 2012 | 559.57 Thousand AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | -100.0% |
| 2004 | 26.97 Thousand AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | - AUD | -100.0% |
| 2024 Q2 | 169.92 Thousand AUD | 0.0% |
| 2024 Q4 | 173.49 Thousand AUD | 0.0% |
| 2023 FY | 189.09 Thousand AUD | -9.86% |
| 2023 Q2 | 192.79 Thousand AUD | 0.0% |
| 2023 Q4 | 189.09 Thousand AUD | 0.0% |
| 2022 Q4 | 209.78 Thousand AUD | 0.0% |
| 2022 FY | 209.78 Thousand AUD | 923.45% |
| 2022 Q2 | 192.79 Thousand AUD | 0.0% |
| 2021 FY | 20.49 Thousand AUD | -66.45% |
| 2021 Q4 | 20.49 Thousand AUD | 0.0% |
| 2021 Q2 | 93.51 Thousand AUD | 0.0% |
| 2020 FY | 61.1 Thousand AUD | 0.0% |
| 2020 Q4 | 61.1 Thousand AUD | 0.0% |
| 2020 Q2 | 178.26 Thousand AUD | 0.0% |
| 2019 Q4 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 FY | - AUD | -100.0% |
| 2018 Q2 | 46.58 Thousand AUD | 0.0% |
| 2017 Q4 | 365.86 Thousand AUD | 0.0% |
| 2017 FY | 365.86 Thousand AUD | -80.75% |
| 2017 Q2 | 678 Thousand AUD | 0.0% |
| 2016 FY | 1.9 Million AUD | 0.0% |
| 2016 Q2 | 1.02 Million AUD | 0.0% |
| 2016 Q4 | 1.9 Million AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2014 FY | - AUD | -100.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 Q4 | 1.14 Million AUD | 0.0% |
| 2013 FY | 1.14 Million AUD | 104.83% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2013 Q1 | - AUD | -100.0% |
| 2012 Q4 | 559.57 Thousand AUD | 0.0% |
| 2012 FY | 559.57 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2005 FY | - AUD | -100.0% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | 26.97 Thousand AUD | 0.0% |
| 2004 FY | 26.97 Thousand AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 123.85 Thousand AUD | -40.08% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 5.65 Million AUD | 96.931% |
| Biome Australia Limited | 1.3 Million AUD | 86.713% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 689.69 Thousand AUD | 74.844% |
| Imugene Limited | 1.54 Million AUD | 88.784% |
| Noxopharm Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 1.11 Million AUD | 84.409% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | 330.48 Thousand AUD | 47.502% |
| Proteomics International Laboratories Limited | 316.39 Thousand AUD | 45.164% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 18.24 Billion AUD | 99.999% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| Race Oncology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | 80.28% |
| Starpharma Holdings Limited | 3.52 Million AUD | 95.082% |
| Nanollose Limited | 42.53 Thousand AUD | -307.94% |
| Memphasys Limited | 4.41 Million AUD | 96.069% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 1.56 Million AUD | 88.891% |
| Island Pharmaceuticals Limited | 421.96 Thousand AUD | 58.884% |
| Nyrada Inc. | - AUD | -Infinity% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.44 Million AUD | 99.005% |
| Dimerix Limited | 149.68 Thousand AUD | -15.91% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 1.22 Million AUD | 85.875% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 1.48 Million AUD | 88.332% |
| Alterity Therapeutics Limited | 159.04 Thousand AUD | -9.087% |
| Biotron Limited | 7130.00 AUD | -2333.338% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| AdAlta Limited | 2.49 Million AUD | 93.045% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 23.59 Thousand AUD | -635.406% |
| Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | 27.507% |
| Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | 78.612% |
| Avecho Biotechnology Limited | 175.15 Thousand AUD | 0.944% |
| Actinogen Medical Limited | 319.06 Thousand AUD | 45.624% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |